Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

View the 50 largest pharmaceutical companies in the world listings here

Merck KGaA

Merck KGaA, Darmstadt, Germany

Rank: 20

Darmstadt, Germany
www.emdgroup.com

2020 Revenues ($USD) : $16,149,714,000
2020 Revenues (foreign currencies) : €14,154,000,000
2020 R&D spend : not available
2020 Number of Employees : not available
Fiscal Year End : 12/31/2020
Key People : Belén Garijo, chairman and CEO; Peter Guenter, member of the executive board, CEO healthcare; Matthias Heinzel, member of the executive board, CEO life science; Marcus Kuhnert, CFO

Significant milestones in 2020 for the Germany-based Merck included FDA approval of its immuno-oncology therapy Bavencio for advanced urothelial cancer treatment. Other approvals included the oral multiple sclerosis therapy Mavenclad, now registered in over 80 countries, including in the U.S. and EU. Merck also secured Japanese approval of its oncology precision medicine Tepmetko, which it developed in-house. –CN

Merck KGaA

Large-scale downstream area at a Merck KGaA facility in Vevey, Switzerland. Image courtesy of Merck KGaA.

Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50